Stock Financial Ratios, Dividends, Split History

BETR / Amplify Snack Brands, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)920.95
Book Value ($M)75.29
Book Value / Share0.98
Price / Book12.23
NCAV ($M)85.56
NCAV / Share1.11
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 76,753,412
Common Stock Shares Outstanding 76,786,000
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Quick Ratio0.84
Current Ratio1.16
Income Statement (mra) ($M)
Cash Flow Statement (mra) ($M)
Cash From Operations0.00
Cash from Investing0.00
Identifiers and Descriptors
Central Index Key (CIK)1640313
Related CUSIPS
03211L952 03211L902

Split History

Stock splits are used by Amplify Snack Brands, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

7 Women-Led S&P 500 Companies to Own for the Long Haul | InvestorPlace

2018-06-13 investorplace
Just 25% of S&P 500 companies have two or more women on their board of directors. For women looking to become a CEO one day, it’s a big problem. (26-0)

Popcorn to Ruby Bars: Chocolatiers Branch Out to Woo Millennials

2018-06-12 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: (19-0)

Trouble in Big Food: America's cereal, soda and soup companies are in turmoil

2018-05-21 money.cnn
General Mills (GIS), Campbell Soup (CPB), Hershey (HSY) and Pepsi (PEP) are all failing to convince investors they have a plan to navigate shoppers' changing tastes. (12-0)

UPDATE 2-Hershey trims sales, gross margin forecasts; shares hit near 2-yr low

2018-04-26 reuters
(Reuters) - Chocolate maker Hershey Co (HSY.N) on Thursday warned of a drop in gross margins due to rising freight and commodity costs, and guided full-year sales to the low end of a prior forecast. (44-0)

Hershey Co Has Become a Molten, Gooey Mess

2018-04-18 investorplace
In retrospect, long-term owners of Hershey Co (NYSE:HSY) are likely wishing they’d taken the sweet buyout offer they got from Mondelez International Inc (NASDAQ:MDLZ) back in 2016. The rival candy and food company was willing to pay $107 per share of Hershey stock at the time. Now it’s trading at less than $97 per share while the broad market is much, much higher for the same timeframe. (50-0)

CUSIP: 03211L102